Oncotelic Therapeutics

Company snapshot

Website

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Oncotelic Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Oncotelic Therapeutics.

1. Jun 8, 2026 Clinical update

   OT-101 — Phase 2

2. Jun 5, 2026 Clinical update

   OT-101 — Phase 2

3. May 23, 2026 Clinical update

   OT-101 — Phase 3

4. May 23, 2026 Clinical update

   Atezolizumab — Phase 2

5. Apr 25, 2026 Partnership signal

   Oncotelic Therapeutics Updates Partnership Strategy for Cancer Drug Development Pipeline

View all clinical trial activity →

• What is Oncotelic Therapeutics?

  Onconic Therapeutics is a pharma organization headquartered in Seoul, KR. It trades on NYSE under ticker OTLC. Primary therapeutic focus areas include Metastatic Lung Non-Small Cell Carcinoma, COVID-19, Malignant Pleural Mesothelioma, Pancreatic Ductal Adenocarcinoma. NovaPharmaN

• Is Oncotelic Therapeutics publicly traded?

  Yes. Oncotelic Therapeutics is listed with ticker OTLC on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Oncotelic Therapeutics develop or market?

  We link 3 drug profile(s) where Oncotelic Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/oncotelic-therapeutics#company-drugs.

• What are the latest developments for Oncotelic Therapeutics?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Oncotelic Therapeutics focus on?

  Oncotelic Therapeutics focuses on Metastatic Lung Non-Small Cell Carcinoma, COVID-19, Malignant Pleural Mesothelioma based on our analysis of their pipeline programs and drug development activities.